Tillotts Pharma Ag

Tillotts Pharma Ag company information, Employees & Contact Information

Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma company with close to 400 employees in Switzerland and abroad. Tillotts is dedicated to the development, acquisition and commercialization of innovative pharmaceutical products for the digestive system. Tillotts successfully markets its own products for the treatment of IBD and Clostridioides difficile infection (CDI) as well as in-licensed products in around 65 countries through its affiliates within Europe and a network of partners throughout the world. At Tillotts, we are dedicated to advancing our employees’ skills and supporting them with their professional development. We encourage individuals’ involvement in all aspects of the business in which they are interested, to gain a deeper insight into the full picture. Working at Tillotts, we can provide you with: • A competitive salary • A good work/life balance • A variety of recognition programmes • Sociable and friendly working environment • Flexible working time • Insurance package At Tillotts, we are committed to honest and ethical business conduct in all of our activities, consistent with all applicable laws and the highest professional standards. We focus on realising the following values: • Passion • Performance • Progress • Accountability • Collaboration • Integrity For more information, visit our career section: https://bit.ly/42Yz7Uo © Tillotts Pharma AG. All rights reserved. See our community guidelines: https://bit.ly/4gEbxPS

Company Details

Employees
294
Address
Baslerstrasse 15, Rheinfelden,4310,switzerland
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Rheinfelden
Looking for a particular Tillotts Pharma Ag employee's phone or email?

Tillotts Pharma Ag Questions

News

Tillotts Pharma and TVM Capital Life Science Announce Formation of Mage Biologics to Develop Innovative Oral Antibody Therapy for Ulcerative Colitis - Yahoo Finance

Tillotts Pharma and TVM Capital Life Science Announce Formation of Mage Biologics to Develop Innovative Oral Antibody Therapy for Ulcerative Colitis Yahoo Finance

Tillotts Pharma in Germany Dedicated to Gastrointestinal Health - PR Newswire

Tillotts Pharma in Germany Dedicated to Gastrointestinal Health PR Newswire

Improving adherence to ulcerative colitis medications: an interview with Mattias Norrman, COO, Tillotts Pharma - News-Medical

Improving adherence to ulcerative colitis medications: an interview with Mattias Norrman, COO, Tillotts Pharma News-Medical

Tillotts Pharma launches new dosage strength of Octasa in Canada - Drug Store News

Tillotts Pharma launches new dosage strength of Octasa in Canada Drug Store News

Tillotts Pharma continues growth with launch in Benelux - The Pharma Letter

Tillotts Pharma continues growth with launch in Benelux The Pharma Letter

Delayed release tablets to treat ulcerative colitis launched in Canada - Labiotech.eu

Delayed release tablets to treat ulcerative colitis launched in Canada Labiotech.eu

Tillotts Pharma AG announces that DIFICLIR TM (fidaxomicin) is recommended for the treatment of Clostridioides difficile infection (CDI) by ESCMID - NTB Kommunikasjon

Tillotts Pharma AG announces that DIFICLIR TM (fidaxomicin) is recommended for the treatment of Clostridioides difficile infection (CDI) by ESCMID NTB Kommunikasjon

European Ulcerative Colitis Patients Have Low Medication Adherence, Tillotts Pharma Survey Shows - Bionews

European Ulcerative Colitis Patients Have Low Medication Adherence, Tillotts Pharma Survey Shows Bionews

AstraZeneca sells gastro drug for $215m to Swiss group Tillotts - Financial Times

AstraZeneca sells gastro drug for $215m to Swiss group Tillotts Financial Times

Pendopharm announces public drug coverage plan listings for Octasa® (oral mesalamine) - PR Newswire Canada

Pendopharm announces public drug coverage plan listings for Octasa® (oral mesalamine) PR Newswire Canada

Switzerland's Tillotts Pharma AG launches ulcerative colitis drug in China - BioSpectrum Asia

Switzerland's Tillotts Pharma AG launches ulcerative colitis drug in China BioSpectrum Asia

Tillotts appoint Dr. Boubekeur as Global Head of Innovation - Pf Media

Tillotts appoint Dr. Boubekeur as Global Head of Innovation Pf Media

PENDOPHARM to distribute ENTOCORT® (budesonide) in Canada for Tillotts Pharma AG - PR Newswire Canada

PENDOPHARM to distribute ENTOCORT® (budesonide) in Canada for Tillotts Pharma AG PR Newswire Canada

Tillotts Pharma UK embracing partnerships - Pf Media

Tillotts Pharma UK embracing partnerships Pf Media

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant